S100A9 and tumor growth

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1404-1405

  Leanderson, Tomas ^a   Ivars, Fredrik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Cancer; Myeloid cells; S100A9; TGF; TLR4

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALGRANULIN B; CYTOKINE; PROBASIN; TASQUINIMOD; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TRICHOSANTHIN;

ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER INHIBITION; CELL FUNCTION; CELL POPULATION; CYTOKINE RELEASE; DOWN REGULATION; DRUG PROTEIN BINDING; EXPERIMENTAL MOUSE; LYMPHOMA; LYMPHOMA CELL; MOLECULAR MECHANICS; MONOCYTE; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; T CELL LYMPHOMA; TREATMENT INDICATION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84885738720     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21027     Document Type: Note

References (10)

1. Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009; 7:97; PMID:19402754; http://dx.doi.org/10.1371/journal.pbio.1000097.
2. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004; 50:3762-71; PMID:15593206; http://dx.doi. org/10.1002/art.20631.
3. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 2005; 11:5146-52; PMID:16033829; http://dx.doi. org/10.1158/1078-0432.CCR-05-0352.
4. Olsson A, Björk A, Vallon-Christersson J, Isaacs JT, Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010; 9:107; PMID:20470445; http://dx.doi.org/10.1186/1476-4598-9-107.
5. Pili R, Häggman M, Stadler WM, Gingrich J, Assikis V, Björk A, et al. Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of Tasquinimod in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer. J Clin Oncol 2011; 29:4022-8; PMID:21931019; http://dx.doi.org/10.1200/JCO.2011.35.6295.
6. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92:3439-43; PMID:7724580; http://dx.doi. org/10.1073/pnas.92.8.3439.
7. Källberg E, Vogl T, Liberg D, Olsson A, Björk P, Wikström P, et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS One 2012; 7:34207; PMID:22470535; http://dx.doi.org/10.1371/journal.pone.0034207.
8. Massagué J. TGFbeta in Cancer. Cell 2008; 134:215-30; PMID:18662538; http://dx.doi.org/10.1016/j.cell.2008.07.001.
9. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29:2035-43; PMID:18689872; http://dx.doi.org/10.1093/carcin/bgn188.
10. Riva M, Källberg E, Björk P, Hancz D, Vogl T, Roth J, et al. Induction of nuclear factor-?B responses by the S100A9 protein is Toll-like receptor-4-dependent. Immunology 2012; 137(2):172-82; PMID:22804476; http://dx.doi.org/10.1111/j.1365-2567.2012.03619.x.